Cite
HARVARD Citation
Jungnik, A. et al. (2023). Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906. Diabetes, obesity & metabolism. 25 (4), pp. 1011-1023. [Online].